Related Experiment Video
Updated: May 30, 2026

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses
Published on: January 20, 2017
Intravenous zanamivir in critically ill patients due to pandemic 2009 (H1N1) influenza A virus
1Department of Infectious Diseases, Singapore General Hospital, Outram Road, Singapore 169608. limin.wijaya@sgh.com.sg
Introduction:
The 2009 (H1N1) influenza A pandemic started in April 2009 and has since spread globally. We have noticed that critically ill patients with confirmed pandemic 2009 (H1N1) influenza A require mechanical ventilation. This paper describes the use of intravenous zanamivir in this group of patients.
Methods:
Patients who had severe pneumonia with 2009 (H1N1) influenza A and required intravenous zanamivir were referred to the Infectious Diseases Department of our institution. Clinical data was collected from these patients. Clinical samples were sent to the National Public Health Laboratory for sequencing.
Results:
A total of five patients used intravenous zanamivir from April 8 to May 8, 2010. Only one death was reported. There were no side effects attributable to the use of intravenous zanamivir. H275 mutation, which confers resistance to oseltamivir, was seen in a subpopulation of the virus in one case.
Conclusion:
Physicians can consider using intravenous zanamivir for the treatment of critically ill patients with 2009 (H1N1) influenza A infection.
More Related Videos
09:31Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
Published on: April 15, 2017
05:21A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection
Published on: August 14, 2019
Related Concept Videos
Influenza
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-IV
Respiratory Syncytial Virus Disease
Inhibitors Of Virion Release
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...